The VVEDIT viral vector platform is currently under development. Once completed, it will specialize in the design and production of “defective” viral vectors—viral particles that can no longer replicate within the host cell or spread in the extracellular environment. The platform will focus on four main types of vectors:
- Adenoviral vectors, known for their strong but transient gene expression, despite triggering an inflammatory response.
- Lentiviral vectors, which integrate into the host genome, enabling stable expression in cell lines.
- Adeno-associated viruses (AAVs), widely used in vivo for their ability to sustain long-term expression with minimal immune response. These will be available in various natural and synthetic serotypes, optimized for targeting specific cell subtypes.
- Genome editing and transgenesis tools, including CRISPR-Cas9 systems, tailored for high-precision genetic modifications.
As construction progresses, VVEDIT aims to become a cutting-edge platform for viral vector development, supporting innovative research in gene therapy and molecular biology.
